Semisynthetic p-Coumaric Acid Derivatives as Lead Dual Inhibitors Against DPP-IV and GSK-3β for Antidiabetic Therapy

Chem Biol Drug Des. 2024 Nov;104(5):e70016. doi: 10.1111/cbdd.70016.

Abstract

Type 2 diabetes mellitus is a dramatically increasing global public health challenge. The prevalence is projected almost double, from 194 million in 2003 to 333 million in 2025 with type 2 diabetes mellitus representing approximately 90%-95% of cases. Dual inhibitors for antidiabetic targets is still novel and promising strategy for discovery of more effective therapies. Ester and triazole derivatives of p-coumaric acid were obtained from Williamson synthesis and Microwave-assisted click reaction, respectively. Chemical structures were finely characterized through IR, 1H, and 13C NMR and HRMS. They were tested for their dual inhibitory activity against GSK-3β kinase and DPP-IV. The complexes resulting from docking were used for all-atom molecular dynamics simulations, including the enzymes in the apo form, using the GROMACS 2022.3. Two inhibitors 2 and 5 demonstrated promising inhibition at low and submicromolar against both proteins. Molecular Dynamic simulations revealed that the binding pattern of the control inhibitors were reproduced by p-coumaric acid derivatives 2 and 5 with crucial interactions involving the same residues. The p-coumaric skeleton can be considered as a promising core for GSK-3β kinase and DPP-IV dual inhibitors.

Keywords: DPP‐IV; GSK‐3β; antidiabetic therapy; enzymatic inhibition; medicinal chemistry; semisynthesis; type 2 diabetes mellitus.

MeSH terms

  • Binding Sites
  • Coumaric Acids* / chemistry
  • Coumaric Acids* / pharmacology
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetes Mellitus, Type 2 / metabolism
  • Dipeptidyl Peptidase 4* / chemistry
  • Dipeptidyl Peptidase 4* / metabolism
  • Dipeptidyl-Peptidase IV Inhibitors / chemical synthesis
  • Dipeptidyl-Peptidase IV Inhibitors / chemistry
  • Dipeptidyl-Peptidase IV Inhibitors / pharmacology
  • Glycogen Synthase Kinase 3 beta* / antagonists & inhibitors
  • Glycogen Synthase Kinase 3 beta* / metabolism
  • Humans
  • Hypoglycemic Agents* / chemical synthesis
  • Hypoglycemic Agents* / chemistry
  • Hypoglycemic Agents* / pharmacology
  • Molecular Docking Simulation*
  • Molecular Dynamics Simulation*
  • Propionates / chemistry
  • Propionates / pharmacology

Substances

  • Coumaric Acids
  • Glycogen Synthase Kinase 3 beta
  • p-coumaric acid
  • Hypoglycemic Agents
  • Dipeptidyl Peptidase 4
  • Propionates
  • Dipeptidyl-Peptidase IV Inhibitors